CN101622012B - 包含丁丙诺啡和纳美芬的改善的药用组合物 - Google Patents

包含丁丙诺啡和纳美芬的改善的药用组合物 Download PDF

Info

Publication number
CN101622012B
CN101622012B CN2008800067678A CN200880006767A CN101622012B CN 101622012 B CN101622012 B CN 101622012B CN 2008800067678 A CN2008800067678 A CN 2008800067678A CN 200880006767 A CN200880006767 A CN 200880006767A CN 101622012 B CN101622012 B CN 101622012B
Authority
CN
China
Prior art keywords
buprenorphine
nalmefene
composition
body weight
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800067678A
Other languages
English (en)
Chinese (zh)
Other versions
CN101622012A (zh
Inventor
克利斯托弗·波恩·夏普利奥
尼尔·海德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Virgin Uk Ltd
Original Assignee
Reckitt Benckiser Healthcare UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser Healthcare UK Ltd filed Critical Reckitt Benckiser Healthcare UK Ltd
Publication of CN101622012A publication Critical patent/CN101622012A/zh
Application granted granted Critical
Publication of CN101622012B publication Critical patent/CN101622012B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2008800067678A 2007-03-01 2008-02-15 包含丁丙诺啡和纳美芬的改善的药用组合物 Expired - Fee Related CN101622012B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0703933A GB2447013A (en) 2007-03-01 2007-03-01 Analgesic composition containing buprenorphone and nalmefene
GB0703933.2 2007-03-01
PCT/GB2008/000522 WO2008104736A1 (en) 2007-03-01 2008-02-15 Improved medicinal compositions comprising buprenorphine and nalmefene

Publications (2)

Publication Number Publication Date
CN101622012A CN101622012A (zh) 2010-01-06
CN101622012B true CN101622012B (zh) 2012-05-30

Family

ID=37965707

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800067678A Expired - Fee Related CN101622012B (zh) 2007-03-01 2008-02-15 包含丁丙诺啡和纳美芬的改善的药用组合物

Country Status (21)

Country Link
US (1) US8497280B2 (enExample)
EP (1) EP2114452B1 (enExample)
JP (1) JP5577102B2 (enExample)
KR (1) KR101437461B1 (enExample)
CN (1) CN101622012B (enExample)
AR (1) AR065582A1 (enExample)
AU (1) AU2008220572B2 (enExample)
BR (1) BRPI0807903A2 (enExample)
CA (1) CA2678568C (enExample)
CL (1) CL2008000607A1 (enExample)
DK (1) DK2114452T3 (enExample)
ES (1) ES2476865T3 (enExample)
GB (1) GB2447013A (enExample)
HR (1) HRP20140591T1 (enExample)
MX (1) MX2009009134A (enExample)
PE (2) PE20120956A1 (enExample)
PL (1) PL2114452T3 (enExample)
PT (1) PT2114452E (enExample)
TW (1) TWI468163B (enExample)
WO (1) WO2008104736A1 (enExample)
ZA (1) ZA200905692B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102128C2 (en) 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
CN102459276B (zh) * 2009-05-25 2016-09-21 H.隆德贝克有限公司 从纳曲酮制备盐酸纳美芬
EP2844236B1 (en) 2012-04-17 2018-12-19 Purdue Pharma LP Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN103637983B (zh) * 2013-12-16 2017-08-04 科贝源(北京)生物医药科技有限公司 一种含有盐酸纳美芬的药物组合物及其制备方法
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN104922061B (zh) * 2015-05-26 2017-09-22 成都天台山制药有限公司 盐酸纳美芬注射液药物组合物和制法
CA3068036A1 (en) 2017-06-30 2019-01-03 Purdue Pharma L.P. Use to buprenorphine in combination with an opioid to treat pain
AU2019224084A1 (en) * 2018-02-22 2020-09-10 Avior, Inc. Transmucosal film composition and methods of making and using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1413110A (zh) * 1999-11-19 2003-04-23 雷克特本克斯尔保健(英国)有限公司 药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
WO1999032120A1 (en) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
EP2049139A4 (en) * 2006-04-24 2009-06-24 Gloucester Pharmaceuticals Inc TREATMENT OF TUMORS EXPRESSING RAS
WO2007146730A2 (en) * 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
US20110015168A1 (en) * 2007-01-19 2011-01-20 Mitchell Keegan Methods for increasing levels of human fetal hemoglobin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1413110A (zh) * 1999-11-19 2003-04-23 雷克特本克斯尔保健(英国)有限公司 药物组合物

Also Published As

Publication number Publication date
JP5577102B2 (ja) 2014-08-20
GB0703933D0 (en) 2007-04-11
PE20120956A1 (es) 2012-08-01
KR101437461B1 (ko) 2014-09-05
DK2114452T3 (da) 2014-06-30
EP2114452A1 (en) 2009-11-11
TWI468163B (zh) 2015-01-11
KR20090115862A (ko) 2009-11-09
HK1139868A1 (en) 2010-09-30
CL2008000607A1 (es) 2008-10-03
US8497280B2 (en) 2013-07-30
CA2678568C (en) 2015-06-16
JP2010520184A (ja) 2010-06-10
PT2114452E (pt) 2014-07-15
ZA200905692B (en) 2010-10-27
AU2008220572B2 (en) 2014-03-27
BRPI0807903A2 (pt) 2014-06-17
PE20090625A1 (es) 2009-06-04
EP2114452B1 (en) 2014-04-09
CN101622012A (zh) 2010-01-06
CA2678568A1 (en) 2008-09-04
AU2008220572A1 (en) 2008-09-04
GB2447013A (en) 2008-09-03
PL2114452T3 (pl) 2014-09-30
WO2008104736A1 (en) 2008-09-04
HRP20140591T1 (hr) 2014-09-12
ES2476865T3 (es) 2014-07-15
US20100152222A1 (en) 2010-06-17
AR065582A1 (es) 2009-06-17
MX2009009134A (es) 2009-09-03
TW200900067A (en) 2009-01-01

Similar Documents

Publication Publication Date Title
CN101626766B (zh) 药用组合物的改进和与药用组合物相关的改进
CA2678481C (en) Improved medicinal compositions comprising buprenorphine and naltrexone
CN101622012B (zh) 包含丁丙诺啡和纳美芬的改善的药用组合物
HK1139868B (en) Improved medicinal compositions comprising buprenorphine and nalmefene
AU2014201782A1 (en) Improved medicinal compositions comprising buprenorphine and naltrexone
AU2014201777A1 (en) Improvements in and relating to medicinal compositions
HK1139867A (en) Improved medicinal compositions comprising buprenorphine and naltrexone
HK1139871B (en) Improvements in and relating to medicinal compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1139868

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1139868

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: RB MEDICAL LTD.

Free format text: FORMER OWNER: RECKITT BENCKISER HEALTHCARE (UK) LIMITED

Effective date: 20121218

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20121218

Address after: Burke County, England

Patentee after: RECKITT BENCKISER HEALTHCARE (UK) LIMITED

Address before: Burke County, England

Patentee before: Reckitt & Benksl Health-Care (England) Ltd.

C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: Burke County, England

Patentee after: The British Virgin UK Ltd

Address before: Burke County, England

Patentee before: RECKITT BENCKISER HEALTHCARE (UK) LIMITED

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120530

Termination date: 20170215

CF01 Termination of patent right due to non-payment of annual fee